<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
20.01.2020 15:31:54

Press Release: Novartis announces EU approval of -2-

a single clinical event suggestive of MS.

In the US, the Sandoz Division of Novartis markets Glatopa(R)

(glatiramer acetate injection) 20mg/mL and 40mg/mL, generic versions of

Teva's glatiramer acetate.

Disclaimer

This press release contains forward-looking statements within the

meaning of the United States Private Securities Litigation Reform Act of

1995. Forward-looking statements can generally be identified by words

such as "potential," "can," "will," "plan," "expect," "anticipate,"

"look forward," "believe," "committed," "investigational," "pipeline,"

"launch," or similar terms, or by express or implied discussions

regarding potential marketing approvals, new indications or labeling for

the investigational or approved products described in this press release,

or regarding potential future revenues from such products. You should

not place undue reliance on these statements. Such forward-looking

statements are based on our current beliefs and expectations regarding

future events, and are subject to significant known and unknown risks

and uncertainties. Should one or more of these risks or uncertainties

materialize, or should underlying assumptions prove incorrect, actual

results may vary materially from those set forth in the forward-looking

statements. There can be no guarantee that the investigational or

approved products described in this press release will be submitted or

approved for sale or for any additional indications or labeling in any

market, or at any particular time. Nor can there be any guarantee that

such products will be commercially successful in the future. In

particular, our expectations regarding such products could be affected

by, among other things, the uncertainties inherent in research and

development, including clinical trial results and additional analysis of

existing clinical data; regulatory actions or delays or government

regulation generally; global trends toward health care cost containment,

including government, payor and general public pricing and reimbursement

pressures and requirements for increased pricing transparency; our

ability to obtain or maintain proprietary intellectual property

protection; the particular prescribing preferences of physicians and

patients; general political and economic conditions; safety, quality or

manufacturing issues; potential or actual data security and data privacy

breaches, or disruptions of our information technology systems, and

other risks and factors referred to in Novartis AG's current Form 20-F

on file with the US Securities and Exchange Commission. Novartis is

providing the information in this press release as of this date and does

not undertake any obligation to update any forward-looking statements

contained in this press release as a result of new information, future

events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives.

As a leading global medicines company, we use innovative science and

digital technologies to create transformative treatments in areas of

great medical need. In our quest to find new medicines, we consistently

rank among the world's top companies investing in research and

development. Novartis products reach more than 750 million people

globally and we are finding innovative ways to expand access to our

latest treatments. About 109,000 people of more than 140 nationalities

work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at

http://twitter.com/novartisnews

For Novartis multimedia content, please visit

www.novartis.com/news/media-library

For questions about the site or required registration, please contact

media.relations@novartis.com

*Clinically isolated syndrome (CIS) is defined as a first episode of

neurologic symptoms that lasts at least 24 hours and is caused by

inflammation or demyelination in the central nervous system(18).

As measured by prolonged time to wheelchair dependence for patients with

SPMS by an average of 4.3 years versus placebo.

References

1. National MS Society Brochure. Disease Modifying Therapies for MS.

http://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Brochure-The-MS-Disease-Modifying-Medications.pdf.

Accessed January 2020.

2. Kappos L, Cree B, Fox R, et al. Siponimod versus placebo in

secondary progressive multiple sclerosis (EXPAND): a double-blind,

randomized, phase 3 study. Lancet. Published online March 22, 2018.

http://dx.doi.org/10.1016/S0140-6736(18)30475-6.

3. Mayzent(R) (siponimod) Summary of Product Characteristics.

Novartis International AG. January 2020.

4. Multiple Sclerosis International Federation. Atlas of MS 2013.

http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf. Accessed

January 2020.

5. Gold R, Kappos L, Bar-Or A, et al. Efficacy of Siponimod in

Secondary Progressive Multiple Sclerosis Patients With Active Disease:

The EXPAND Study Subgroup Analysis. P750. 35th Congress of the European

Committee for Treatment and Research in Multiple Sclerosis, September

2019.

6. Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective

sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte

distribution and has species-specific effects on heart rate. Brit J

Pharm. 2012; 167:1035-47.

7. Tavares A, Barret O, Alagille D, et al. Brain distribution of

MS565, an imaging analogue of siponimod (BAF312), in non-human primates.

Eur J Neurol. 2014;21(Suppl 1):504-PP2067.

8. Briard E, Rudolph B, Desrayuad S, et al. MS565: A SPECT tracer of

evaluating the brain penetration of BAF312 (siponimod). Chem Med Chem.

2015; 10(6):1008-18.

9. Bigaud M, Perdoux J, Ramseier P et al.

Pharmacokinetic/Pharmacodynamic Characterization of Siponimod (BAF312)

in Blood versus Brain in Experimental Autoimmune Encephalomyelitis Mice.

Neurology. 2019;P2.2-066.

10. Mannioui A, Vauzanges Q, Fini JB, et al. The Xenopus tadpole: An in

vivo model to screen drugs favoring remyelination. Mult Scler.

2018:24(11):1421-32.

11. Martin E, Urban B, Beerli C, et al. Siponimod (BAF312) is a potent

promyelinating agent: preclinical mechanistic observation. P1376. 35th

Congress of the European Committee for Treatment and Research in

Multiple Sclerosis, September 2019.

12. Dietrich M, Hecker C, Ramseier P, et al. Neuroprotective potential

for siponimod (BAF312) revealed by visual system readouts in a model of

experimental autoimmune encephalomyelitis-optic neuritis (EAEON). P844.

35th Congress of the European Committee for Treatment and Research in

Multiple Sclerosis, September 2019.

13. Vermersch P, Gold R, Kappos L, et al. Siponimod Delays the Time to

Wheelchair in Patients with SPMS: Results from the EXPAND study. 35th

Congress of the European Committee for Treatment and Research in

Multiple Sclerosis (ECTRIMS), September 2019.

14. National Multiple Sclerosis Society. Definition of MS.

https://www.nationalmssociety.org/What-is-MS/Definition-of-MS. Accessed

January 2020.

15. MS Society. Types of MS.

https://www.mssociety.org.uk/what-is-ms/types-of-ms. Accessed January

2020.

16. National Multiple Sclerosis Society. Secondary Progressive MS

(SPMS).

https://www.nationalmssociety.org/What-is-MS/Types-of-MS/Secondary-progressive-MS.

Accessed January 2020.

17. Hauser S. Efficacy and safety of ofatumumab versus teriflunomide in

relapsing multiple sclerosis: results of the phase 3 ASCLEPIOS I and II

trials. Oral presentation. ECTRIMS 2019.

18. National MS Society. Clinically Isolated Syndrome (CIS).

https://www.nationalmssociety.org/Symptoms-Diagnosis/Clinically-Isolated-Syndrome-(CIS).

Accessed January 2020.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Antonio Ligi Michael Amos

Novartis External Communications Novartis Global Pharma Communications

+41 61 324 1374 (direct) +41 61 324 2705 (direct)

antonio.ligi@novartis.com +41 79 123 7806 (mobile)

Eric Althoff michael.amos@novartis.com

Novartis US External Communications

+1 862 778 3243

+1 646 438 4335

eric.althoff@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 862 778 3258

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

(END) Dow Jones Newswires

January 20, 2020 09:32 ET (14:32 GMT)